Evotec and Bristol Myers Squibb Strengthen Proteomics Collaboration

Evotec SE announced an expansion of its strategic partnership with Bristol Myers Squibb to further develop molecular glue degraders beyond oncology. This extension was marked by a US$50 million payment to Evotec, with further milestone-based payments possible.

Since the 2018 inception and notable expansion in 2022, this collaboration has aimed to build a pipeline of molecular glue-based therapies. Evotec has utilized Bristol Myers Squibb’s CELMoDs™ to innovate beyond oncological applications, maintaining leadership in drug discovery while addressing unmet medical needs.

The partnership benefits from Evotec's PanOmics and PanHunter platforms, which enhance drug discovery and candidate selection through comprehensive data analysis. The collaboration exemplifies a commitment to offering novel therapeutic options with longer-lasting effects by exploring diverse targets and applications.